BioMedNewsBreaks – MetAlert Inc. (MLRT) Announces Launch of Its Next-Gen SmartSole in Sweden

MetAlert (OTC: MLRT) today announced the launch of its new 4G GPS SmartSole in Sweden through its distribution partner Posifon AB. The upgraded GPS SmartSole introduction will be an important part of the national service agreement Posifon recently secured with major municipalities across Sweden related to providing home care, personal tracking and security for seniors. Initial shipments of the GPS SmartSole will be distributed to health care organizations, from memory care clinics to hospitals and social care organizations throughout Sweden. “We are excited to launch this next generation 4G Cat M1 GPS SmartSole in one of Europe’s most advanced health care countries when it comes to addressing the needs of Alzheimer’s and dementia patients,” said MetAlert Director Andrew Duncan. “Our partner Posifon has done an incredible job in securing national distribution channels after many years of trials and evaluation by the Swedish authorities.”

To view the full press release, visit https://ibn.fm/aE2ya

About MetAlert Inc.

MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing, selling and licensing products, services and intellectual property in the GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring sectors. With over 20 years of experience and an extensive patent portfolio, MetAlert is a leading solution provider for consumers/patients afflicted with movement, cognitive and spatial awareness disorders. This market represents approximately 2.9% of the world’s population. The company offers global end-to-end hardware, software and connectivity solutions, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products, enterprise and government agency applications. Utilizing the latest in miniaturized, low power consumption GPS, cellular, RF, NFC, and BLE technologies, caregivers are enabled to track and monitor patients in real time. The company is known for its game-changing and award-winning patented GPS SmartSole(R) — think Dr. Scholl’s meets LoJack, the world’s first invisible wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism, and traumatic brain injury. MetAlert’s subscription-based business model is built around technology innovation with intellectual property protection. The company has international distributors servicing customers around the globe with subscribers in over 40 countries. MetAlert is a U.S. military government contractor and has other customers that include public health authorities, municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers. For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW
Breaks Categories: News

Recent Posts

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Signs Four-Year Exclusive Distribution Agreement for GelrinC (R) in Israel

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced…

4 hours ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Files Supplement to Shareholder Meeting Materials Clarifying Share Consolidation Terms

Quantum BioPharma (NASDAQ: QNTM) announced that it has filed a supplement to its Sept. 28,…

3 days ago

BioMedNewsBreaks – Earth Science Tech Inc. (ETST) Builds Long-Term Value Through Strategic Integration

Earth Science Tech (OTCQB: ETST), a diversified holding company operating across healthcare, pharmacy, technology, telemedicine,…

4 days ago

BioMedNewsBreaks – Why Adaptogenics Health Corp. (CSE: ADPT) Is ‘One to Watch’

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…

4 days ago

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands NAMs Strategy to Advance BiTAC(R) Therapies

VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant preclinical testing methods across its…

1 week ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Taps Thermo Fisher’s Clinical Research Business for Lucid-MS Trial

Quantum BioPharma (NASDAQ: QNTM) has signed a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical…

1 week ago